RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Strategy

Home  >  Investor Relations  >  At a glance  >  Strategy

QIAGEN is executing a focused strategy to build value through profitable growth opportunities in the expanding market for molecular analysis.

We are a global leader in Sample to Insight solutions, with a portfolio of technologies to empower customers from start to finish in the molecular analysis process. In a challenging world, our approach is to help customers achieve molecular insights faster, better and more efficiently.

Over more than three decades we have built a unique competitive advantage for QIAGEN: deep relationships with customers across the continuum from academic research, to pharmaceutical development, to molecular diagnostics and other applications. We partner with researchers in creating molecular testing technologies in the early stages, then develop and commercialize promising applications and platforms as these methods emerge in healthcare and industry.

Our strategy contains a focus on 5 pillars of growth where we have novel technologies targeting >$6 billion in opportunities out of our >$11 billion total addressable market. In these areas we are aligning our investments to maximize sales in proven high-growth markets.

Unwavering focus on five pillars of growth

QIAGEN’s 5 pillars of growth

  • Sample technologies: Market leading portfolios of instruments and consumables for extracting nucleic acids (DNA, RNA, proteins) from samples in research and clinical workflows
  • QIAcuity: Digital PCR platforms with ground breaking microplate technology backed by wide range of content
  • QIAstat-Dx: Syndromic testing platform enabling rapid, accurate and comprehensive detection of a collection of pathogens in clinical settings
  • NeuMoDx: Integrated PCR testing platforms for clinical testing labs with unparalleled ease of use
  • QuantiFERON: The gold standard test for modern tuberculosis testing with unique automation capabilities

We are investing in menu expansion of these systems to drive strong installed base growth and sustainable consumables sales.

Executing on a roadmap to fuel robust growth beyound 2021

QIAGEN is committed to innovation in molecular testing, through cutting-edge R&D at our centres of excellence and targeted acquisitions that expand our presence in growing fields.

QIAGEN is making a long-term difference in our world by making improvements in life possible.